Academic Press Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy

Nearly 44 million people have Alzheimer’s or related dementia worldwide, according to the Alzheimer’s Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer’s and other forms of dementia.First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer’s disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer’s disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer’s diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer’s disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer’s disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. Review A complete overview of recent studies on cognitive, clinical, neural, and therapeutic aspects of Alzheimer’s disease From the Back Cover Nearly 44 million people have Alzheimer’s or a related dementia worldwide, according to the Alzheimer’s Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer’s and other forms of dementia. First, readers are introduced to the cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to symptoms and the quality of life in Alzheimer’s disease. In addition, some chapters discuss recent studies on memory dysfunction in advanced-stage Alzheimer’s disease, in comparison to early-stage Alzheimer’s disease, including a chapter on the factors underlying transition from mild cognitive impairment to Alzheimer’s disease. Following this section, some chapters present recent studies on the role of different cortical and subcortical structures in the development of different symptoms in Alzheimer’s disease as well as different neural biomarkers underlying the development and treatment of Alzheimer’s disease. In the last section of the book, therapeutic aspects of Alzheimer’s disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, in Alzheimer’s disease are reviewed. Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy aid readers with keeping up with the advances in research and care making it a prime tool for clinicians, psychologists, researcher, neurologists, and caregivers of dementia patients. About the Author Dr. Ahmed Moustafa is a Professor of Psychology and Computational Modeling at School of Psychology, Bond University, Gold Coast, Queensland, Australia. Prior to moving to Bond University, Ahmed was an associate professor in Psychology and Neuroscience at Marcs Institute for Brain, Behaviour, and Development & School of Psychology, Western Sydney University. Ahmed is trained in computer science, psychology, neuroscience, a